Virpax Pharmaceuticals, Inc. financial data

Symbol
VRPX on OTC
Location
Berwyn, PA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2024 - 03 Mar 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 52% % -81%
Debt-to-equity -209% % -454%
Return On Assets -637% % -499%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 26,562,581 shares 2168%
Common Stock, Shares, Outstanding 14,887,581 shares 1171%
Entity Public Float $1,466,500 USD -84%
Common Stock, Value, Issued $149 USD 1142%
Weighted Average Number of Shares Outstanding, Basic 4,254,403 shares 263%
Weighted Average Number of Shares Outstanding, Diluted 4,254,403 shares 263%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $5,819,308 USD 14%
General and Administrative Expense $6,260,627 USD -41%
Operating Income (Loss) $12,079,935 USD 23%
Nonoperating Income (Expense) $8,126 USD -94%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $16,889,398 USD 6.3%
Net Income (Loss) Attributable to Parent $12,067,225 USD 21%
Earnings Per Share, Basic -3 USD/shares 78%
Earnings Per Share, Diluted -3 USD/shares 78%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current $1,555,614 USD -84%
Assets $1,555,614 USD -84%
Liabilities, Current $2,469,374 USD -68%
Liabilities $2,469,374 USD -68%
Retained Earnings (Accumulated Deficit) $71,611,360 USD -20%
Stockholders' Equity Attributable to Parent $913,760 USD -147%
Liabilities and Equity $1,555,614 USD -84%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $7,729,332 USD -285%
Net Cash Provided by (Used in) Financing Activities $453,951 USD
Common Stock, Shares Authorized 100,000,000 shares 0%
Common Stock, Shares, Issued 14,887,581 shares 1171%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1,513,057 USD -83%
Deferred Tax Assets, Valuation Allowance $18,331,000 USD 15%
Deferred Tax Assets, Gross $18,331,000 USD 15%
Deferred Tax Assets, Operating Loss Carryforwards $12,487,000 USD 41%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Additional Paid in Capital $70,697,451 USD 15%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $134,699 USD -75%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%